Aben Minerals
OTCMKTS:ABNAFAben Minerals Ltd. engages in the acquisition and exploration of mineral properties primarily in British Columbia, Saskatchewan, and Yukon, Canada. The company primarily explores for gold and graphite deposits. Its flagship project is the Forrest Kerr Gold project that covers an area of 23,397 hectares located in northwestern British Columbia. The company was formerly known as Aben Resources Ltd. and changed its name to Aben Minerals Ltd. in February 2023. Aben Minerals Ltd. was incorporated in 1960 and is headquartered in Vancouver, Canada.
Toubani Resources
OTCMKTS:AGGFFToubani Resources Inc. engages in the exploration and development of gold properties in West Africa. It focuses on the Kobada Gold project located in Southern Mali. The company was formerly known as African Gold Group, Inc. and changed its name to Toubani Resources Inc. in June 2022. Toubani Resources Inc. was incorporated in 2002 and is headquartered in Toronto, Canada.
Alacer Gold
OTCMKTS:ALIAFAlacer Gold Corp. engages in the mining, development, and exploration of mineral deposits in Turkey. It primarily holds an 80% interest in the Ãöpler gold mine that is located in the Erzincan Province, east-central Turkey. The company was incorporated in 1993 and is based in Denver, Colorado.
Burning Rock Biotech
NASDAQ:BNRBurning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.